## Mutation and Polymorphism Report

Authors:	ors: A.S.B. Khoo <sup>1</sup> , P. Balraj <sup>1</sup> , A. Rachedi <sup>2</sup> , C.N. Chin <sup>3</sup> , and L. Volpi <sup>1</sup>								
Affiliations:	<ul> <li><sup>1</sup> Division of Molecular Pathology, Institute for Medical Research, 50588 Kuala Lumpur, Malaysia;</li> <li><sup>2</sup> Centre for Gene Analysis and Technology, Faculty of Life Science, National University of Malaysia, 43000 Bangi, Malaysia (Current Address: Department of Biochemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong);</li> <li><sup>3</sup> Department of Pediatrics, Kuantan Hospital, Kuantan, Malaysia</li> </ul>								
Corresponding Author Address and E-mai			il: Dr. Alan Khoo, Division of Molecular Pathology, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia Phone: +(603)-4402421/4402423 Fax: +(603)-2934114 E-mail: alankhoo@imr.gov.my						
Title : Keywords:	A novel complex mutation of the OTC (ornithine transcarbamylase) gene in a Malaysian pedigree ornithine transcarbamylase, OTC, indel mutation, urea cycle, infant, newborn								
Species:	Human								
Change is:	mutation								
U									
Gene/Locus									
Name: ornithin		ornithine	ne carbamoyltransferase (ornithine transcarbamylase)						
Symbol: O		OTC	C						
Genbank accession number:		K02100	K02100						
<b>OMIM accession number:</b> 31		311250	250						
Locus specific database:		http://ww	tp://www.peds.umn.edu/otc						
Chromosomal location: Xp2		Xp21.1	.1						
Inheritance: X-linke		X-linked	ed						
Mutation / polymorphism name									
Nucleotide	change-Systematic	name:	c.813 indel AG>C						
Amino acid change–Trivial name:			stop 288						
Mutation / polymorphism type:			indel mutation, frameshift						
Polymorphism	n frequency:								
Detection method:			Direct DNA Sequencing						
Detection conditions:			Primers: 5'-ttactgtcccatgaagttatttaacc-3' 5'-ggaattaatgaacctgagagagcat-3'						

## Standard 30 cycle PCR, annealing temperature 55 C

Di	agnosis method developed: Mutati	Mutation disrupts normal MnII restriction site					
Ev	vidence for existence and effect of mutation:						
			Yes	No	Don't know		
1.	1. Base change found on repeat PCR sample						
2.	Base change segregates or appears with trait	Х					
3.	Base change affects conserved residue	Х					
	Expression analysis supports hypothesis for ca	usation			X		
5.	Normals tested (50 required)		Х				
	ncillary data Haplotype association :						
		Malay					
	Ethnic background/Population association :	•					
3.	Geographic association :	Malaysi	а				
4.	Frequency (of mutation) in population:						
5.	Clinical phenotype of proband :	Severe neonatal hyperammonemia					
6.	Homologous allele (if recessive trait):						
7.	PIC: (if microsatellite)						
8.	Other:						
9.	Present in HGMD listing: (http://www.cf.ac.uk/uwcm/mg/hgmd0.html)	Yes:	No: X				

## **Comments**

The propositus, presented with clinical symptoms at day 2 of life and had a strong family history of multiple early neonatal deaths in males. PCR and direct sequencing using primer sequences of Matsuura et al. (1993) revealed an innocent polymorphism (L101F) (Tuchman and Plante, 1995) and a complex mutation consisting of deletions of A and G of nucleotides 813 and 814 respectively in exon 8 (the third nucleotide of codon 271 and the first nucleotide of codon 272) which were replaced by an insertion of C ( c.813 indel AG > C). The indel mutation caused a frame shift which resulted in a stop codon (TGA) occurring 17 amino acids downstream the first mutant codon. The frameshift also resulted in the 17 amino acid (DRRRKSGSRLSKVTRLQ) sequence being different from corresponding wild type sequence of the human OTC (EEEKKKRLOAFOGYOVT) (Hata et al., 1988). The predicted amino acid sequence would result in a truncated protein of 287 amino acid (the wild type being 355 aa). (The mutation was named based on the cDNA sequence of the OTC precursor protein (Horwich et al., 1984) beginning from position 136 of the mRNA sequence Gen Bank Acc No. K02100 ie. the same numbering system used in HGMD). Acknowledgments

This project was supported by the Ministry of Science, Technology and Environment IRPA Project Fund No. 06-05-01-0137. The authors wish to thank the Director of the Institute for Medical Research for permission to publish this paper. The authors also wish to thank Prof. Ch'ng SL from the University of Malaya, Kuala Lumpur, Mr. Leong Weng Choy from the Pharmacy Department, Kuantan Hospital, Prof. Boo Nem Yun from the National University of Malaysia as well as staff of the Centre for Gene Analysis & Technology of the National University of Malaysia, staff of the Institute for Medical Research, Kuala Lumpur and staff of the Kuantan Hospital for their contributions.

## References

Hata A, Tsuzuki T, Shimada K, Takiguchi M, Mori M, Matsuda I (1988) Structure of the human ornithine transcarbamylase gene. J Biochem 103: 302-308

Horwich AL, Fenton WA, Williams KR, Kalousek F, Krau JP, Doolittle RF. Konigsberg W, Rosenberg LE (1984) Structure and expression of a complementary DNA for the nuclear coded precursor of human mitochondrial ornithine transcarbamylase. Science 224: 1068-1074

Matsuura T, Hoshide R, Setoyama C, Shimada K, Hase Y, Yanagawa T, Kajita M, Matsuda I (1993) Four novel gene mutations in five Japanese male patients with neonatal or late onset OTC deficiency: application of PCR- single-strand- conformation polymorphisms for all exons and adjacent introns. Hum Genet 92: 49-56

Tuchman M; and Plante, RJ; (1995) Mutations & polymorphisms in the human ornithine transcarbamylase gene: Mutation update addendum. Hum Mutat. 5(4):293-295.